Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform designed to give clinicians rapid, safe, and accurate assessments of hemodynamic function in the office or clinic, to help them better diagnose and manage heart failure and pulmonary hypertension and improve patient outcomes. CPS has received FDA Breakthrough Device designation. The company's regulatory history includes FDA 510(k) clearance in 2018 for an algorithm for non-invasive measurement of ejection fraction.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/13/26	$6,000,000	Venture	Colle Capital Orlando Health Ventures	undisclosed